These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 23394096)
1. Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD. Carulli L; Maurantonio M; Hebbard L; Baldelli E; Loria P; George J Curr Pharm Des; 2013; 19(29):5280-96. PubMed ID: 23394096 [TBL] [Abstract][Full Text] [Related]
2. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
3. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice. Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070 [TBL] [Abstract][Full Text] [Related]
4. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870 [TBL] [Abstract][Full Text] [Related]
5. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. Stein LL; Dong MH; Loomba R Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118 [TBL] [Abstract][Full Text] [Related]
6. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance]. Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125 [TBL] [Abstract][Full Text] [Related]
8. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back. Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F Tumori; 2013; 99(1):10-6. PubMed ID: 23548993 [TBL] [Abstract][Full Text] [Related]
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on ballooning degeneration in nonalcoholic steatohepatitis (NASH): when to use metformin in nonalcoholic fatty liver disease (NAFLD). Doycheva I; Loomba R Adv Ther; 2014 Jan; 31(1):30-43. PubMed ID: 24385405 [TBL] [Abstract][Full Text] [Related]
11. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Sugimoto K; Inui H; Fukusato T World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263 [TBL] [Abstract][Full Text] [Related]